Statin therapy and plasma free fatty acids: A systematic review and meta-analysis of controlled clinical trials

Sahebkar, A. and Simental-Mendía, L. E. and Pedone, C. and Ferretti, G. and Nachtigal, P. and Bo, S. and Derosa, G. and Maffioli, P. and Watts, G. F. (2016) Statin therapy and plasma free fatty acids: A systematic review and meta-analysis of controlled clinical trials. British Journal of Clinical Pharmacology, 81 (5). pp. 807-818.

[img] Text

Download (685kB)


AIM The aim of this meta-analysis was to evaluate the effect of statin therapy on plasma FFA concentrations in a systematic review and meta-analysis of controlled clinical trials. Methods PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched (from inception to February 16 2015) to identify controlled trials evaluating the impact of statins on plasma FFA concentrations. A systematic assessment of bias in the included studies was performed using the Cochrane criteria. A random effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderators. Results Meta-analysis of data from 14 treatment arms indicated a significant reduction in plasma FFA concentrations following treatment with statins (weighted mean difference (WMD) -19.42, 95 CI -23.19, - 15.64, P < 0.001). Subgroup analysis confirmed the significance of the effect with both atorvastatin (WMD -20.56, 95 CI -24.51, -16.61, P < 0.01) and simvastatin (WMD -18.05, 95 CI -28.12, -7.99, P < 0.001). Changes in plasma FFA concentrations were independent of treatment duration (slope -0.10, 95 CI -0.30, 0.11, P = 0.354) and magnitude of reduction in plasma low density lipoprotein cholesterol concentrations (slope 0.55, 95 CI -0.17, 1.27, P = 0.133) by statins. Conclusions The results of the present study suggest that statin therapy may lower plasma FFA concentrations. The cardiovascular and metabolic significance of this finding requires further investigation. © 2015 The British Pharmacological Society.

Item Type: Article
Additional Information: Cited By :16 Export Date: 16 February 2020 CODEN: BCPHB Correspondence Address: Simental-Mendía, L.E.Predio Canoas 100, Mexico; email:
Uncontrolled Keywords: cholesterol dyslipidaemia fatty acid meta-analysis statins atorvastatin hydroxymethylglutaryl coenzyme A reductase inhibitor low density lipoprotein cholesterol simvastatin bibliographic database cholesterol blood level clinical assessment controlled clinical trial (topic) data extraction data synthesis fatty acid blood level human meta analysis priority journal publishing quality control quantitative analysis Review risk factor sensitivity analysis systematic review treatment duration blood Cardiovascular Diseases metabolism randomized controlled trial (topic) Cholesterol, LDL Fatty Acids, Nonesterified Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Randomized Controlled Trials as Topic
Subjects: QV pharmacology
QY Clinical Pathology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 29 Feb 2020 06:58
Last Modified: 29 Feb 2020 06:58

Actions (login required)

View Item View Item